Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C

doi:10.3748/wjg.v23.i21.3815

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9919)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

640

WORD

352

HTML

3741

Tables (1-5)

247

Sum=4980

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1711

Download

3228

Sum=4939

Jun 7, 2017 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jun 7, 2017; 23(21): 3815-3824
Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3815

Table 5 Association between IFNL3 (IL28B) gene single nucleotide polymorphism and relapse after pegylated interferon alpha and ribavirin treatment in chronic hepatitis C patients

SNP	Allele/genotype	Relapse (n = 39), n (%)	Non-relapse (n = 38), n (%)	Relapse vs non-relapse	OR (95%CI)	P value
rs4803217 (C/A)	C/A	38 (48.72)/40 (51.28)	56 (73.68)/20 (26.32)	C vs A	0.339 (0.173-0.667)	0.001^a
	CC	7 (17.95)	21 (55.26)	CC vs CA + AA	0.177 (0.063-0.500)	0.0007^a
	CA	24 (61.54)	14 (36.84)	CC + CA vs AA	0.332 (0.081-1.364)	0.113
	TT	8 (20.51)	3 (7.89)	Dose of C allele	0.296 (0.134-0.653)	0.002^a
rs12979860 (C/T)	C/T	40 (51.28)/38 (48.72)	52 (68.42)/24 (31.58)	C vs T	0.486 (0.252-0.937)	0.030^a
	CC	8 (20.51)	18 (47.37)	CC vs CT + TT	0.287 (0.105-0.783)	0.013^a
	CT	24 (61.54)	16 (42.11)	CC + CT vs TT	0.538 (0.143-2.013)	0.351
	TT	7 (17.95)	4 (10.53)	Dose of C allele	0.442 (0.211-0.925)	0.028^a
rs8099917 (T/G)	T/G	56 (71.79)/22 (28.21)	52 (68.42)/24 (31.58)	T vs G	1.175 (0.589-2.344)	0.647
	TT	21 (53.85)	17 (44.74)	TT vs TG + GG	1.304 (0.526-3.233)	0.566
	TG	14 (35.90)	18 (47.37)	TT + TG vs GG	0.750 (0.156-3.560)	1.000
	GG	4 (10.26)	3 (7.89)	Dose of T allele	1.174 (0.582-2.365)	0.649
rs12980275 (A/G)	A/G	45 (57.69)/33 (42.31)	56 (73.68)/20 (26.32)	A vs G	0.487 (0.247-0.961)	0.037^a
	AA	12 (30.77)	22 (57.89)	AA vs AG + GG	0.323 (0.127-0.825)	0.017^a
	AG	21 (53.85)	12 (31.58)	AA + AG vs GG	0.647 (0.167-2.503)	0.737
	GG	6 (15.38)	4 (10.53)	Dose of A allele	0.495 (0.245-0.998)	0.046^a

^aP < 0.05. SVR: Sustained virological response.

Citation: Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol 2017; 23(21): 3815-3824
URL: https://www.wjgnet.com/1007-9327/full/v23/i21/3815.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i21.3815